News & publications
Press releases, publications and events from Spiral Therapeutics.
Spiral Therapeutics Announces $27 Million Series B Financing and Strategic Partnership with Advanced Bionics
SOUTH SAN FRANCISCO, Calif., April 14, 2026 — Spiral Therapeutics, Inc. (“Spiral Therapeutics” or “Spiral”), a clinical-stage company developing novel therapies for inner ear disorders, today announced the…
Read more
Spiral Therapeutics Announces Successful Completion of the SPT-2101 PHASE 1b/2a Clinical Trial for Meniere’s Disease, Data Presented During the 2024 AAO Annual Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 — Spiral Therapeutics, Inc. (Spiral), a clinical-stage company focused on developing novel therapies for inner ear disorders, announced the successful completion of the…
Read more
Spiral Therapeutics Receives Hearing Technology Innovator Award
SOUTH SAN FRANCISCO, Calif., August 30, 2023 — Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company focused on delivering therapies for inner ear disorders, today announced today that it has been…
Read more
Spiral Therapeutics Announces Collaboration with the Vestibular Disorders Association (VeDA), Advancing Patient-Centric Care in Neurotology
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 — Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage pharmaceutical company leading the way in therapies for inner ear disorders, today announced a strategic partnership with…
Read more
Spiral Therapeutics Welcomes New Investment, Cementing Its Leadership in Neurotology
SOUTH SAN FRANCISCO, Calif., August 30, 2023 — Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company focused on delivering therapies for inner ear disorders, today announced a new round of financing…
Read more
Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to Board
SOUTH SAN FRANCISCO, Calif., March 29, 2023 — Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company focused on delivering therapies for inner ear disorders, announced today the completion of its acquisition…
Read more
Spiral Therapeutics Completes $8.25M Financing and Initiates Phase 2 Trial in Ménière’s Disease
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 — Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company focused on delivering therapies for inner ear disorders, today announced that the Company…
Read more